Cover Image
市場調查報告書

中國的醫藥品用玻璃包裝產業分析

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

出版商 ResearchInChina 商品編碼 299557
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的醫藥品用玻璃包裝產業分析 China Pharmaceutical Glass Packaging Industry Report, 2014-2017
出版日期: 2015年06月02日 內容資訊: 英文 60 Pages
簡介

2013年時,中國的醫藥品用玻璃瓶市場規模達800億個(相當於25∼30萬噸)。塑膠、鋁箔和其他新素材的替代,及醫療改革伴隨的包裝材料購買價格的低迷,中國的醫藥品用玻璃包裝產業持續低迷狀態。同時,進入障礙低,低級、中級品市場陷入嚴重的設備過剩狀態,高級品市場仍依賴進口商品。現在,已開發國家偏好高品質、耐水性、天然性的硼硅酸玻璃,不過,中國至今仍主要供給低品質的硼硅酸玻璃和鈉、鈣玻璃,以及「半天然性」硼硅酸玻璃(化學的穩定性不滿足自然必要條件,重金屬含有量不明,尺寸不正確)。注射用的預填充式注射器,中國主要依賴來自外資型企業的進口。

本報告提供中國的醫藥品包裝用玻璃產業相關分析、整體市場結構和生產量、消費量趨勢預測、各部門的詳細趨勢、對外貿易狀況、主要的國內、外資型企業簡介與業績等調查,並將其結果為您概述為以下內容。

第1章 醫藥品用玻璃包裝材料概要

  • 定義與分類
  • 相關產業

第2章 中國的醫藥品用玻璃產業的發展

  • 現狀
  • 市場規模
  • 競爭模式
  • 進出口
  • 預填充式注射系統
    • 定義與分類
    • 現狀
    • 競爭模式
    • 價格分析
  • 下游的需求
    • 疫苗
    • 血液製劑
    • 胰島素
    • 肝素
    • 干擾素
    • rhG-CSF(基因重組人類G-CSF製劑)
  • 發展趨勢

第3章 主要醫藥品用玻璃企業

  • Becton, Dickinson and Company
    • 簡介
    • 經營情形
    • 收益結構
    • 醫藥品用包裝材料產業
    • 中國的產業發展
  • Gerresheimer AG
  • SCHOTT AG
  • Nipro
  • Shandong Pharmaceutical Glass
  • Shandong Weigao Group Medical Polymer Co., Ltd.
  • Cangzhou Four Stars Glass
  • Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
  • Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
  • Linuo Glassworks Group

第4章 摘要與預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: ZYM065

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Chinese pharmaceutical packaging market reached RMB72 billion, up 10.6% from a year earlier.

As a traditional form of pharmaceutical packaging bottle, pharmaceutical glass bottle took up a large proportion of the Chinese pharmaceutical packaging market in initial development stage of the packaging market. However, affected by negative factors like the substitution of new packaging materials (plastics and aluminum foil) and continuous decline in purchase prices of packaging materials quoted by pharmaceutical companies due to reform in medical system, China pharmaceutical glass packaging industry has developed sluggishly, with its market share standing at estimated 45% or so for the time being.

Due to low barrier to entry, China's pharmaceutical glass industry has been large but not strong as a whole, with low and medium-end products struggling with huge overcapacity and high-end products relying on imports. At present, developed countries around the world all use level I waterproof neutral borosilicate glass, while China still mostly adopts low borosilicate glass, soda-lime glass and almost domestically unique "semi-neutral borosilicate pharmaceutical glass" (its chemical stability cannot meet neutral requirements; the heavy metal content in glass is not defined clearly; dimensions are not accurate).

The production of neutral borosilicate glass faces dual barriers of raw materials and tube-making technology, which have been still controlled by foreign companies so far, resulting in persistently high production costs and limited applications. In 2012, German Schott AG, a world well-known pharmaceutical glass company, together with Zhejiang Xinkang Pharmaceutical Glass Co., Ltd., announced to establish a joint venture that would engage in pharmaceutical packaging, an important sign marking localization of pharmaceutical glass. But, even for the joint venture, it has to buy glass tube produced by Schott abroad.

However, the defect of low borosilicate glass easily flaking causes safety risks to health of users, so it is imperative to promote neutral borosilicate glass. Market demand for neutral borosilicate glass pharmaceutical containers has been growing by more than 20% over the past two years. More and more pharmaceutical players started to use neutral borosilicate glass, especially for high value-added products. For example, Buchang Pharma employs neutral borosilicate glass packaging materials for all its Danhong Injections, and some innovative R&D-oriented pharmaceutical companies like Jiangsu Hengrui Medicine Co., Ltd. also adopt neutral borosilicate glass.

With years of development and competition, the Chinese pharmaceutical glass business market still finds a relatively low level of concentration, but competitively leading companies have emerged in some market segments, especially in prefilled syringe market.

There are only five companies that have obtained assemblages for prefilled syringes in China, i.e., foreign-funded BD and Gerresheimer and domestic Shandong Weigao Group Medical Polymer, Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd. and Shandong Pharmaceutical Glass Co., Ltd.

By virtue of first-mover advantage and developed marketing network, Shandong Weigao Group Medical Polymer sold about 85.85 million prefilled syringes in 2014, accounting for more than 50% of the market in China, followed by foreign brands such as BD and Gerresheimer with market share of about 25%, and Zibo Minkang Pharmaceutical and Shandong Pharmaceutical Glass (the remaining). In addition, Shandong Weigao Group Medical Polymer still plans to implement the 50-million prefilled syringes project, which is expected to further raise the company's share in prefilled system market.

China Pharmaceutical Glass Packaging Industry Report, 2014-2017 highlights the followings:

  • Status quo, market size, import & export, downstream demand and development forecast of China pharmaceutical glass industry;
  • Status quo, competitive landscape and price of China prefilled syringe industry;
  • Operation, pharmaceutical glass business and development prospects of 4 global and 6 domestic pharmaceutical glass packaging companies.

Table of Contents

1 Overview of Pharmaceutical Glass Packaging Materials

  • 1.1 Definition and Classification
  • 1.2 Industry Chain

2 Development of China Pharmaceutical Glass Industry

  • 2.1 Status Quo
  • 2.2 Market Size
  • 2.3 Competitive Landscape
  • 2.4 Import & Export
  • 2.5 Prefilled Injection System
    • 2.5.1 Definition and Classification
    • 2.5.2 Status Quo
    • 2.5.3 Competitive Landscape
    • 2.5.4 Price
  • 2.6 Downstream Demand
    • 2.6.1 Vaccine
    • 2.6.2 Blood Product
    • 2.6.3 Insulin
    • 2.6.4 Heparin
    • 2.6.5 Interferon
    • 2.6.6 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
  • 2.7 Development Trend

3 Major Pharmaceutical Glass Companies

  • 3.1 Becton, Dickinson and Company
    • 3.1.1 Profile
    • 3.1.2 Operation
    • 3.1.3 Revenue Structure
    • 3.1.4 Pharmaceutical Packaging Materials Business
    • 3.1.5 Business in China
  • 3.2 Gerresheimer AG
    • 3.2.1 Profile
    • 3.2.2 Operation
    • 3.2.3 Revenue Structure
    • 3.2.4 Business in China
  • 3.3 SCHOTT AG
    • 3.3.1 Profile
    • 3.3.2 Operation
    • 3.3.3 Pharmaceutical Packaging Materials Business
    • 3.3.4 Business in China
  • 3.4 Nipro Medical Corporation
    • 3.4.1 Profile
    • 3.4.2 Operation
    • 3.4.3 Revenue Structure
    • 3.4.4 Pharmaceutical Packaging Materials Business
    • 3.4.5 Business in China
    • 3.4.5.1 ChengDuPingYuanNipro Pharmaceutical Packaging Co., Ltd.
    • 3.4.5.2 Jilin NiproJiaheng Pharmaceutical Packaging Co., Ltd.
    • 3.4.5.3 Anyang NiproChangda Pharmaceutical Packaging Co., Ltd.
  • 3.5 Shandong Pharmaceutical Glass Co., Ltd
    • 3.5.1 Profile
    • 3.5.2 Operation
    • 3.5.3 Revenue Structure
    • 3.5.4 Gross Margin
    • 3.5.5 Development Prospects and Forecast
  • 3.6 Shandong Weigao Group Medical Polymer Co., Ltd.
    • 3.6.1 Profile
    • 3.6.2 Operation
    • 3.6.3 Revenue Structure
    • 3.6.4 Gross Margin
    • 3.6.5 R&D and Investment
    • 3.6.6 Major Customers
    • 3.6.7 Pharmaceutical Packaging Materials Business
    • 3.6.8 Development Prospects and Forecast
  • 3.7 Cangzhou Four Stars Glass Co., Ltd.
  • 3.8 Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
  • 3.9 Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
  • 3.10 Linuo Glassworks Group

4 Summary and Forecast

Selected Charts

  • Classification and Applications of Pharmaceutical Glass
  • New Pharmaceutical Glass Packaging and Application
  • Diagram of Pharmaceutical Glass Packaging Industry Chain
  • Market Size of China Pharmaceutical Packaging Industry, 2010-2014
  • Output of Human Powder Injection (Including Freeze-dried) and Injection in China, 2010-2014
  • Output of Large Volume Parenterals (LVPs) in China, 2010-2014
  • Revenue and YoY Growth of Veterinary Drug Industry in China, 2007-2014
  • Import and Export Volume of Glass Ampoule in China, 2011-2014
  • Import and Export Value of Glass Ampoule in China, 2011-2014
  • Average Import and Export Price of Glass Ampoule in China, 2011-2014
  • Materials for Prefilled Syringes
  • Classification of Prefilled Syringe and Structural Diagram
  • Prefilled Syringe Suppliers in China and Their Products
  • Major Prefilled Syringe Manufacturers and Their Capacity, 2014
  • Price of Some Prefilled Drugs in China, 2010-2014
  • Market Size of Pharmaceuticals Industry in China, 2011-2015
  • Lot Release Volume of EPI an Extra EPI in China, 2007-2014
  • Lot Release Volume of Blood Products in China by Product, 2008-2014
  • Market Size of Insulin Drugs in China, 2007-2014
  • Theoretical Capacity of Heparin Sodium API in China, 2008-2014
  • Market Size and YoY Growth of Heparin Preparations in China, 2007-2014
  • Market Size and Sales Volume of Recombinant Interferon in China, 2013-2019E
  • Market Size and Sales Volume of rhG-CSF in China, 2013-2019E
  • List of Primary Businesses of BD
  • Revenue and Operating Income of BD, FY2010-FY2014
  • Revenue Structure of BD by Business, FY2013-FY2014
  • Revenue Structure of BD by Region, FY2013-FY2014
  • BD's Revenue Breakdown from Medical Business by Product, FY2011-FY2014
  • Revenue Structure of Gerresheimer by Consumption Market, 2014
  • Revenue and Operating Income of Gerresheimer, 2009-2014
  • Revenue Breakdown of Gerresheimer by Business, 2009-2014
  • Revenue Structure of Gerresheimer by Region, 2014
  • Revenue and Profit of SCHOTT, FY2013-FY2014
  • Revenue Breakdown of SCHOTT by Region, FY2013-FY2014
  • SCHOTT's Subsidiaries in China
  • Revenue and Net Income of Nipro, FY2010-FY2014
  • Revenue Structure of Nipro by Business, FY2013-FY2014
  • Revenue Structure of Nipro by Region, FY2014
  • Nipro's Revenue from Glass Products Business and % of Total Revenue, FY2012-FY2014
  • Nipro's Key Subsidiaries in China and Their Businesses
  • List of Main Products of Shandong Pharmaceutical Glass
  • Revenue and Net Income of Shandong Pharmaceutical Glass, 2008-2015
  • Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Product, 2008-2014
  • Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Region, 2008-2014
  • Gross Margin of Shandong Pharmaceutical Glass by Product, 2008-2014
  • Revenue and Gross Margin of Shandong Pharmaceutical Glass, 2014-2017E
  • Variety of Products and Main Products of Shandong Weigao Group Medical Polymer
  • Revenue and Net Income of Shandong Weigao Group Medical Polymer, 2009-2014
  • Revenue Breakdown of Shandong Weigao Group Medical Polymer, 2013-2014
  • Main High Value-added Conventional Medical Consumables of Shandong Weigao Group Medical Polymer
  • Revenue Breakdown of Shandong Weigao Group Medical Polymer by Region, 2008-2014
  • Prefilled Syringe Output and Sales of Shandong Weigao Group Medical Polymer, 2011-2014
  • Market Size of Pharmaceutical Packaging Industry in China, 2014-2017E
Back to Top